These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17154043)

  • 1. [Liver damage in treatment of latent tuberculous infection by isoniazid].
    Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
    Kekkaku; 2006 Nov; 81(11):651-60. PubMed ID: 17154043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid].
    Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
    Kekkaku; 2007 Jan; 82(1):1-9. PubMed ID: 17310776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survey of anti-tuberculosis drug-induced severe liver injury in Japan].
    Shigeto E;
    Kekkaku; 2007 May; 82(5):467-73. PubMed ID: 17564126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
    Ito K
    Kekkaku; 2016 Sep; 91(9):607-616. PubMed ID: 30646464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
    Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
    Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
    Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers.
    Wu SS; Chao CS; Vargas JH; Sharp HL; Martín MG; McDiarmid SV; Sinatra FR; Ament ME
    Transplantation; 2007 Jul; 84(2):173-9. PubMed ID: 17667808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
    Hahn JA; Ngabirano C; Fatch R; Emenyonu NI; Cheng DM; Adong J; Tumwegamire A; Terrault NA; Linas BP; Jacobson KR; Muyindike WR
    AIDS; 2023 Aug; 37(10):1535-1543. PubMed ID: 37260251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
    Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
    J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe isoniazid-associated hepatitis--New York, 1991-1993.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Jul; 42(28):545-7. PubMed ID: 8326947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    Nolan CM; Goldberg SV; Buskin SE
    JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis.
    Ikegame S; Wakamatsu K; Fujita M; Nakanishi Y; Kajiki A
    J Infect Chemother; 2011 Aug; 17(4):530-3. PubMed ID: 21188445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
    Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW
    Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.